Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Undisclosed-2
- Development stage
- Preclinical
- Lead developer
- Suzhou Siran Biotech
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Undisclosed-2 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Suzhou Siran Biotechnology for the treatment of metabolic syndrome. The drug candidate utilizes a dual-target approach, designed to simultaneously silence two distinct molecular targets involved in the pathogenesis of metabolic dysfunction. It leverages the company's proprietary delivery technology, likely incorporating the Stork-W platform for dual-targeting and the Stork-X platform for adipose tissue-specific delivery. By specifically targeting adipose tissue, the therapy aims to modulate metabolic pathways at their source to improve systemic health while minimizing off-target effects. The specific molecular targets of this siRNA remain undisclosed.
- Other names
- Suzhou Siran metabolic syndrome siRNA
Beyond the preview
Go deeper on Undisclosed-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Undisclosed-2.